

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding the CITADEL-205 trial evaluating the efficacy of parsaclisib for relapsed/refractory (R/R) mantle cell lymphoma?**
  - Overall response rate for patients who had previously received ibrutinib was greater with daily parsaclisib
  - Overall response rate for patients who had previously received ibrutinib was greater with weekly parsaclisib
  - Overall response rate was <10% for all patients receiving parsaclisib
  - Overall response rate was >10% for all patients receiving parsaclisib
- 2. Which of the following agents demonstrated superior progression-free survival (HR 0.65) for patients with R/R Hodgkin lymphoma in the KEYNOTE-204 trial?**
  - Brentuximab vedotin
  - Pembrolizumab
  - Nivolumab
  - Bortezomib
- 3. Which of the following adverse events is the most common with the EZH2 inhibitor tazemetostat among patients with follicular lymphoma?**
  - Back pain
  - Pyrexia
  - Gastrointestinal symptoms
  - Headache
- 4. Which of the following drug types best describes the novel agent loncastuximab tesirine, approved for patients with R/R diffuse large B-cell lymphoma?**
  - Anti-CD79b antibody
  - CD3 x CD20 bispecific antibody
  - CD20-directed antibody-drug conjugate
  - CD19-directed antibody-drug conjugate